Peter Eweje, MD
Gastroenterology · Jacksonville, NCNPI 1871538363
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $315 and has fallen 85.1% since, to $47 in 2025. That places this record below the midpoint for gastroenterology clinicians in NC, where the typical reported total is $1,694.
Across 15 payments — averaging $34.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$106
- Dova Pharmaceuticals$98
- Shionogi Inc$93
- Gilead$86
- Ipsen Biopharmaceuticals, Inc$47
- Boston Scientific$20
- plus $68 from 4 others
Across 38 payments — averaging $4702.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$140K
- Bristol Myers Squibb$23K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- Bausch Health US, LLC$500
What the payments were for
- Consulting fees$122%
- Food & beverage$50698%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$518 in reported general payments places this provider in the 25th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 36 | $42,589 |
| Mesalamine | 27 | $6,839 |
| Colestipol Hcl | 35 | $5,412 |
| Mesalamine ErMesalamine | 16 | $4,150 |
| Ursodiol | 25 | $3,971 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 208 | $3,941 |
| Pantoprazole Sodium | 391 | $3,031 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 183 | $2,841 |
| Balsalazide Disodium | 12 | $2,723 |
| Dexlansoprazole DrDexlansoprazole | 20 | $2,609 |
| Omeprazole | 177 | $2,351 |
| Lansoprazole | 75 | $2,226 |
| Mercaptopurine | 25 | $2,150 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 90 | $1,372 |
| Sucralfate | 20 | $1,123 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Jacksonville
- Stephen DealCharlotte$945K
- Fred FowlerCharlotte$932K
- Paul WatkinsChapel Hill$876K
- Nilesh LodhiaCharlotte$735K
- Evan DellonChapel Hill$431K
- Robert ReindollarSalisbury$430K
- Andrew StormWinston Salem$426K
- John PoulosFayetteville$407K
- Manal AbdelmalekDurham$402K
- Christopher McGowanCary$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.